Form 8-K - Current report:
SEC Accession No. 0001193125-23-082785
Filing Date
2023-03-29
Accepted
2023-03-29 06:06:30
Documents
12
Period of Report
2023-03-28
Items
Item 1.02: Termination of a Material Definitive Agreement

Document Format Files

Seq Description Document Type Size
1 8-K d483536d8k.htm   iXBRL 8-K 23834
  Complete submission text file 0001193125-23-082785.txt   144864

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA crvs-20230328.xsd EX-101.SCH 2866
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE crvs-20230328_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE crvs-20230328_pre.xml EX-101.PRE 11272
6 EXTRACTED XBRL INSTANCE DOCUMENT d483536d8k_htm.xml XML 3356
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

EIN.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37719 | Film No.: 23771618
SIC: 2834 Pharmaceutical Preparations